|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||73.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FDA in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor Genmab to receive ...
Categories: Yahoo FinanceGet free summary analysis Genmab A/S reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Genmab A/S – Agenus Inc., Lexicon Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc. and OncoMed Pharmaceuticals, Inc. (AGEN-US, LXRX-US, IONS-US and OMED-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)
Preliminary data shows responses achieved in 11 of 34 evaluable patients with cervical cancer treated with tisotumab vedotin Next steps in clinical development of tisotumab vedotin in this indication under ...